Ovarian Cancer
Refractory ovarian cancer responds to antiangiogenic bevacizumab combination therapy
Published in Women's Health Weekly, August 24th, 2006
"The study was undertaken to determine the safety and efficacy of the monoclonal, antivascular endothelial growth factor antibody bevacizumab in combination with cytotoxic chemotherapy for women with platinum-refractory ovarian cancer. A retrospective analysis of women who received bevacizumab in combination with a cytotoxic agent was performed," scientists writing in the journal Cancer report.
According to J.D. Wright and colleagues, Washington University, "Response was determined by measurable disease or assessment of serial cancer antigen (CA) 125...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Breast Cancer
Adult weight gain is associated with increased risk of breast cancer in postmenopausal women - Breast Cancer
Women with breast cancer are cautioned against phytoestrogens for menopausal symptoms - Dental Research
Hormones may play key role in notable gender differences in dental caries rates - Diet & Nutrition
Consumption of soy protein versus meat affects calcium absorption in women - Osteoporosis
Nitric oxide polymorphisms may not be associated with bone strength in older women - Alcohol Use
Marital therapy may be more effective at treating female alcoholics than traditional methods - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
